Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY

touchCONGRESS for ONCOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice.  The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCPs outside of the USA and UK. This activity is funded by an independent medical education grant from GSK.  This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:  XXX

touchCONGRESS for touchHAEMATOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice.  The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCPs outside of the USA and UK. This activity is funded by an independent medical education grant from GSK.  This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:  XXX

touchEXPERT OPINIONS for touchONCOLOGY Listen to a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes. The experts Dr David S Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Dr Eileen M O’Reilly, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA Dr Rebecca S Heist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA This touchPODCAST is for healthcare professionals outside of the UK.   This activity is funded by an independent medical education grant from Revolution Medicines.   This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.   For further information visit our website:  https://touchoncologyime.org/mutations-and-personalized-cancer-care-targeting-the-future/  

touchPANEL DISCUSSION for touchONCOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition.   The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#

touchPANEL DISCUSSION for touchHAEMATOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition.   The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#

touchFOCUS for touchRESPIRATORY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:  www.touchrespiratory.org/ADCs-in-NSCLC

touchFOCUS for touchONCOLOGY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchoncology.org/ADCs-in-NSCLC

touchSYMPOSIUM for touchHAEMATOLOGY Listen to this touchSYMPOSIUM recorded live in December 2024 preceding the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, USA.  Symposium chair Prof. Cindy Neunert is joined by Dr María Eva Mingot Castellano and Prof. David Kuter to discuss the impact of immune thrombocytopenia (ITP) on patients and review current and emerging treatment strategies. Session 1: Prof. Cindy Neunert considers how ITP affects patients' lives, including the impact on health-related quality of life  Session 2: Dr Mingot Castellano discusses two illustrative patient cases and the application of current management strategies  Session 3: Prof. David Kuter reviews emerging targeted treatment options for ITP, with a focus on their mechanisms of action and the latest data  Session 4: A panel discussion with all three faculty on shared decision-making and collaboration in the clinic  This touchPODCAST is for HCPs in the USA. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME.  For further information visit our website: touchoncologyime.org

touchSYMPOSIUM for touchHAEMATOLOGY Listen to this touchSYMPOSIUM recorded live in December 2024 preceding the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, USA.  Symposium chair Prof. Cindy Neunert is joined by Dr María Eva Mingot Castellano and Prof. David Kuter to discuss the impact of immune thrombocytopenia (ITP) on patients and review current and emerging treatment strategies. Session 1: Prof. Cindy Neunert considers how ITP affects patients' lives, including the impact on health-related quality of life  Session 2: Dr Mingot Castellano discusses two illustrative patient cases and the application of current management strategies  Session 3: Prof. David Kuter reviews emerging targeted treatment options for ITP, with a focus on their mechanisms of action and the latest data  Session 4: A panel discussion with all three faculty on shared decision-making and collaboration in the clinic  This touchPODCAST is for HCPs in the USA. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME.  For further information visit our website: touchhaematologyime.org  

touchEXPERT FOCUS for touchONCOLOGY Listen to three experts provide insights into the optimal management of neurofibromatosis type 1 (NF1) in paediatric and adult patients, with a focus on plexiform neurofibromas (PNs). Strategies for ensuring the smooth transitioning of paediatric patients into the adult care system are also considered. The experts Dr AeRang Kim, Children's National Hospital, Washington, DC, USA Dr Rebecca Brown, University of Alabama School of Medicine, Birmingham, AL, USA Dr Kaleb Yohay, NYU Langone Health, New York, NY, USA This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from Springworks  Therapeutics, Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchoncologyime.org/expert-focus-management-of-nf1/